

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – May 9, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. April 11, 2012 DUR Minutes – Vote
 - B. April 12, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for January 2012
 - B. Retrospective Drug Utilization Review Response for November 2011
 - C. Medication Coverage Activity for April 2012
 - D. Pharmacy Help Desk Activity for April 2012

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote on New Citalopram Safety Alert Limitations – See Appendix C.**
 - A. Background
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

6. **Action Item – Annual Review of Atypical Antipsychotics – See Appendix D.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Poly-Pharmacy Review
 - E. Market Update
 - F. MEDNET Update
 - G. COP Recommendations
 - H. Utilization Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Miscellaneous Anti-Infectives and 30 Day Notice to Prior Authorize Keflex® – See Appendix E.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30 Day Notice to Prior Authorize Duexis® – See Appendix F.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details
 - G. Duexis® Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Glaucoma Medications and 30 Day Notice to Prior Authorize Zioptan™ – See Appendix G.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details
 - G. Zioptan™ Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 10. Utilization Review of Gonadotropin Releasing Products – See Appendix H.**
 - A. Central Precocious Puberty Overview
 - B. Treatment Options
 - C. Utilization Details
 - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 11. FDA and DEA Updates – See Appendix I.**

- 12. Future Business**
 - A. Utilization Review of Botulinum Toxin Products
 - B. Annual Review of Synagis[®]
 - C. New Product Reviews
 - D. Medical Product Reviews

- 13. Adjournment**